-
公开(公告)号：US10906967B2
公开(公告)日：2021-02-02
申请号：US16669375
申请日：2019-10-30
Applicant: PROTHENA BIOSCIENCES LIMITED , UNIVERSITY HEALTH NETWORK
Inventor： Tarlochan S. Nijjar , Avijit Chakrabartty , Jeffrey N. Higaki
Abstract: The invention provides antibodies that specifically bind to transthyretin (TTR). The antibodies can be used for treating or effecting prophylaxis of diseases or disorders associated with TTR accumulation or accumulation of TTR deposits (e.g., TTR amyloidosis). The antibodies can also be used for diagnosing TTR amyloidosis and inhibiting or reducing aggregation of TTR, among other applications.
-
公开(公告)号：US20210009595A1
公开(公告)日：2021-01-14
申请号：US16880192
申请日：2020-05-21
Applicant: UNIVERSITY HEALTH NETWORK
Inventor： Radoslaw Laufer , Grace Ng , Sze-Wan Li , Heinz W. Pauls , Yong Liu , Narendra Kumar B. Patel
IPC: C07D487/04 , C07D519/00
Abstract: The present teachings provide a compound represented by the following structural formula: (Formula (I)); or a pharmaceutically acceptable salt thereof. Also described are pharmaceutical compositions and methods of use thereof.
-
公开(公告)号：US10772992B2
公开(公告)日：2020-09-15
申请号：US15999308
申请日：2017-02-16
Inventor： Paul Santerre , Soror Sharifpoor , Wey Liang Leong
Abstract: A soft tissue filler comprising a biodegradable amino-acid derived polycarbonate-urethanes and methods of repairing soft tissue defects are provided. The biodegradable soft tissue filler comprises a porous scaffold that is the reaction product of: a) a divinyl oligomer component that comprises a carbonate-derived divinyl oligomer that is the reaction product of a lysine-derived diisocyanate, a vinyl coupling agent, and a polycarbonate and, optionally, an ether-derived divinyl oligomer, wherein the ether-derived divinyl oligomer is the reaction product of a lysine-derived diisocyanate, a vinyl coupling agent, and an ether; b) at least one anionic monomer; and c) at least one hydrophobic monomer. The molar ratio of (a):(b+c) is between about 1:≥21 and about 1:30, the soft tissue filler has a porosity of >75%; and a compressive moduli of between about 1 kPa and about 50 kPa.
-
公开(公告)号：US20200230144A1
公开(公告)日：2020-07-23
申请号：US16635320
申请日：2018-08-01
Applicant: UNIVERSITY HEALTH NETWORK
Inventor： Mark Robert Bray , Jacqueline M. Mason , Tak W. Mak , Graham Fletcher
IPC: A61K31/519 , A61K39/395 , A61P35/00
Abstract: Provided herein are methods of treating cancer using an effective amount of a compound represented by the formula: (I) or a pharmaceutically acceptable salt thereof and an effective amount of an immune checkpoint inhibitor. Also provided are compositions comprising the same compound represented by the formula shown above or a pharmaceutically acceptable salt thereof and an immune checkpoint inhibitor.
-
65.发明授权公开(公告)号：US10685461B1
公开(公告)日：2020-06-16
申请号：US16228512
申请日：2018-12-20
Inventor： Chung Chan , Zhou Yu , Jian Zhou , Patrik Rogalla , Bernice Hoppel , Kurt Walter Schultz
Abstract: A method and apparatus is provided to iteratively reconstruct a computed tomography (CT) image using a spatially-varying content-oriented regularization parameter, thereby achieving uniform statistical properties within respective organs/regions and different statistical properties (e.g., degree of smoothing and noise level) among the respective organs/regions. For example, less smoothing and sharper features/resolution can be applied within a lung region than within a soft-tissue region by using a smaller regularization parameter value in the lung region than in the soft-tissue region. This can be achieved, e.g., using a minimum intensity projection to suppress/eliminate sub-solid nodules in the lung region. The content-oriented regularization parameter can be generated by reconstructing an initial CT image, which is then segmented/classified according to organs and/or tissue type. Segmenting the image and generating the content-oriented regularization parameter can be integrated into one process by applying an HU-to-β mapping to the CT image.
-
Patent Agency Ranking
公开(公告)号：US10669330B2
公开(公告)日：2020-06-02
申请号：US16129618
申请日：2018-09-12
Applicant: PROTHENA BIOSCIENCES LIMITED , UNIVERSITY HEALTH NETWORK
Inventor： Yue Liu , Tarlochan S. Nijjar , Avijit Chakrabartty , Jeffrey N. Higaki
Abstract: The invention provides antibodies that specifically bind transthyretin (TTR). The antibodies can be used for treating or effecting prophylaxis of diseases or disorders associated with TTR accumulation or accumulation of TTR deposits (e.g., TTR amyloidosis). The antibodies can also be used for diagnosing TTR amyloidosis and inhibiting or reducing aggregation of TTR, among other applications.
-
公开(公告)号：US20200157494A1
公开(公告)日：2020-05-21
申请号：US16109202
申请日：2018-08-22
Applicant: UNIVERSITY HEALTH NETWORK , THE HOSPITAL FOR SICK CHILDREN
Inventor： Gordon KELLER , Shinichiro OGAWA , Anand GHANEKAR , Christine BEAR , Binita M. KAMATH , Mina OGAWA , James SURAPISITCHAT
IPC: C12N5/071
Abstract: Methods for producing hepatocyte and/or cholangiocyte lineage cells from pluripotent stem cells, the method comprising (a) specifying the extended nodal agonist treated induced endodermal cell population to obtain a cell population comprising hepatocyte and/or cholangiocyte progenitors by contacting the extended nodal agonist treated induced endodermal cell population with specification media comprising a FGF agonist and a BMP4 agonist and/or active conjugates and/or fragments thereof; (b) inducing maturation, and optionally further lineage specification and/or expansion of the hepatocyte and/or cholangiocyte progenitors of the cell population to obtain a population comprising hepatocyte lineage cells such as hepatoblasts, hepatocytes and/or cholangiocytes, the inducing maturation step comprising generating aggregates of the cell population. Optionally, the method also comprises activating the cAMP pathway within the aggregates and forming co-aggregates.
-
公开(公告)号：US20200087386A1
公开(公告)日：2020-03-19
申请号：US16584634
申请日：2019-09-26
Applicant: PROTHENA BIOSCIENCES LIMITED , UNIVERSITY HEALTH NETWORK
Inventor： YUE LIU , TARLOCHAN S. NIJJAR , AVIJIT CHAKRABARTTY , JEFFREY N. HIGAKI
Abstract: The invention provides antibodies that specifically bind transthyretin (TTR). The antibodies can be used for treating or effecting prophylaxis of diseases or disorders associated with TTR accumulation or accumulation of TTR deposits (e.g., TTR amyloidosis). The antibodies can also be used for diagnosing TTR amyloidosis and inhibiting or reducing aggregation of TTR, among other applications.
-
公开(公告)号：US10561687B2
公开(公告)日：2020-02-18
申请号：US15550572
申请日：2016-02-17
Applicant: UNIVERSITY HEALTH NETWORK
Inventor： Gordon Keller , Stephanie Protze
Abstract: Provided are methods for producing compositions comprising a population of cardiomyocytes enriched for or substantially devoid of sinoatrial node-like pacemaker cardiomyocytes (SANLCM) from human pluripotent stem cells (hPSCs), and methods of use thereof.
-
公开(公告)号：US20200046768A1
公开(公告)日：2020-02-13
申请号：US16536948
申请日：2019-08-09
Applicant: University Health Network
Inventor： Li Zhang , Dalam Ly , Linan Fang
Abstract: Methods for the treatment of cancer using double negative T cells (DNTs) and a PD-1 or PD-L1 inhibitor are described. Tumors treated with DNTs and a PD-1 inhibitor exhibited increased DNT cell infiltration and increased cytotoxicity towards non-small cell lung cancer (NSCLC) cells. Also described are compositions and kits comprising DNTs and a PD-1 or PD-L1 inhibitor and their use for the treatment of cancer.
-
-
-
-
-
-
-
-
-
Search Results
585
records
(took 0.031 seconds)
